06:47:35 Europe / Stockholm
Svenska | English

EXACT Therapeutics

Share price & Turnover

Share price change and turnover during the day of this press release

Calendar

2024-09-30 Half year report
2024-06-28 Annual General meeting
2024-06-10 Ex-date Ordinary Dividend EXTX 0.00 NOK
2024-04-18 Year-end Report 2023
2023-09-28 Half year report
2023-06-12 Ex-date Ordinary Dividend EXTX 0.00 NOK
2023-06-09 Annual General meeting
2023-04-21 Year-end Report 2022
2022-09-22 Half year report
2022-06-09 Ex-date Ordinary Dividend EXTX 0.00 NOK
2022-06-08 Annual General meeting
2022-04-27 Year-end Report 2021
2021-08-25 Half year report
2021-06-01 Annual General meeting
2021-05-14 Ex-date Ordinary Dividend EXTX 0.00 NOK
2021-04-29 Year-end Report 2020
2020-07-27 Split EXTX 1:250
2020-07-24 Extra General Meeting 2020

Description

CountryNorway
ListEuronext Growth Oslo
SectorHealth care
IndustryBiotechnology
EXACT Therapeutics är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar exempelvis tekniska plattformar för läkemedelstestning. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och mervärdesprodukter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Bolaget gick tidigare under namnet Phoenix Solutions och har idag sitt huvudkontor i Oslo.
EXTX: EXACT Therapeutics minutes from Annual General Meeting June 9, 2023
2023-06-09 12:39:50 
OSLO, 9 June 2023: EXACT Therapeutics AS ("EXACT-Tx", "the Company" Euronext
Growth: EXTX) held its Annual General Meeting on June 9th 2023 at 10:30 CEST. 

All proposed resolutions were approved.

Please find enclosed the minutes of the meeting including appendices. The
minutes will also be available on the the company website: www.exact-tx.com


ENDS
For more information, please contact:

Per Walday, CEO
EXACT Therapeutics
Email per.walday@exact-tx.com

John M. Edminson CFO 
EXACT Therapeutics 
Email: john.edminson@exact-tx.com

About EXACT-Tx
EXACT-Tx is a Norwegian clinical-stage precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101)
activated by ultrasound for enhanced drug targeting deployed in multiple
indications to enhance the therapeutic efficacy of medicines through the use of
ultrasound-mediated drug delivery, for patients across multiple diseases.
www.exact-tx.com
Source Oslo Børs
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

An email has been sent to the given address. To login please click "Login" in that email to verify your account

Companies

Press releases